The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of 5-weekly S-1 plus cisplatin (CDDP) combination with trastuzumab (Tmab) for HER2-positive advanced gastric or esophagogastric junction (EGJ) cancer: WJOG7212G (T-SPACE) study.
 
Yuji Miura
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Toshimi Takano
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Yasutaka Sukawa
No Relationships to Disclose
 
Katsuhiko Nosho
No Relationships to Disclose
 
Shuichi Hironaka
Honoraria - Taiho Pharmaceutical
 
Misuzu Mori
No Relationships to Disclose
 
Kazuhiro Nishikawa
Honoraria - Ajinomoto; Chugai Pharma; Taiho Pharmaceutical; TERUMO; Tsumura & Co.; Yakult Pharmaceutical
Research Funding - Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Shinya Tokunaga
No Relationships to Disclose
 
Hiroyuki Okuda
No Relationships to Disclose
 
Masahiro Tsuda
No Relationships to Disclose
 
Keisei Taku
No Relationships to Disclose
 
Kazuo Nishikawa
No Relationships to Disclose
 
Toshikazu Moriwaki
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Sanofi; Sawabe; Taiho Pharmaceutical
 
Kenichi Yoshimura
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Taiho Pharmaceutical
 
Ichinosuke Hyodo
Honoraria - Taiho Pharmaceutical